Filing Details

Accession Number:
0000899243-22-029564
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-23 20:19:16
Reporting Period:
2022-08-19
Accepted Time:
2022-08-23 20:19:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
895051 Casi Pharmaceuticals Inc. CASI Biological Products, (No Disgnostic Substances) (2836) 581959440
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1573160 James Huang C/O Casi Pharmaceuticals, Inc.
9620 Medical Center Dr. Suite 300
Rockville MD 20850
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-08-19 171,116 $3.27 171,116 No 4 P Indirect See Footnote
Common Stock Acquisiton 2022-08-22 23,105 $3.46 194,221 No 4 P Indirect See Footnote
Common Stock Acquisiton 2022-08-23 40,000 $3.50 234,221 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 191 Direct
Footnotes
  1. The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.075 to $3.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  2. Represents securities held by Panacea Opportunity Fund I, L.P., over which the reporting person may be deemed to indirectly share beneficial ownership. The reporting person disclaims such beneficial ownership except to the extent of his pecuniary interest therein, if any.
  3. The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.24 to $3.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.46 to $3.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.